Leerink Partners raises Brii Biosciences stock price target to HK$2.00 on HBV data

Leerink Partners doubled its price target on Brii Biosciences Ltd (HK:2137) to HK$2.00, maintaining a Market Perform rating, following the company's first-half 2025 financial report and clinical program updates. This upgrade is primarily driven by new data from the ENSURE study's Cohort 4 for BRII-179, which demonstrated robust anti-Hepatitis B Surface Antigen responses and the potential for shorter treatment duration, prompting ongoing discussions with China's CDE for Phase 3. Financially, Brii reduced H1 2025 R&D and administrative expenses by 7.3% and 26.0% respectively, and reported a strong cash position of US$289.9 million, sufficient to fund operations through 2028.

Analysis

Leerink Partners has significantly re-evaluated Brii Biosciences Ltd (HK:2137), doubling its price target to HK$2.00 while maintaining a Market Perform rating. The primary driver for this revision is promising new clinical data from Cohort 4 of the ENSURE study for its Hepatitis B drug, BRII-179. The data demonstrated robust anti-Hepatitis B Surface Antigen responses and suggested the potential for a shorter, 24-week treatment duration, a development that has prompted engagement with China's Center for Drug Evaluation regarding a potential Phase 3 study. Financially, the company has demonstrated strong operational discipline, reducing R&D and administrative expenses by 7.3% and 26.0% respectively compared to the first half of 2024. This fiscal prudence, combined with a cash position of US$289.9 million, provides a sufficient runway to support operations through 2028, substantially de-risking the company from near-term financing needs. The combination of a doubled price target with a neutral rating suggests that while the asset's potential is now viewed more favorably, significant clinical and regulatory milestones remain, with key follow-up data anticipated in the second half of 2025.

Key Decisions for Investors

• Investors should view the maintained 'Market Perform' rating as a note of caution, suggesting that despite the positive clinical data, the stock may be perceived as fairly valued until further pivotal milestones are met.
• The primary catalyst to monitor is the 24-week follow-up data from the ENSURE Cohort 4 study, expected in H2 2025, as its outcome will be critical for initiating the Phase 3 trial and will heavily influence future valuation.
• The company's strong cash position of US$289.9 million, providing a runway through 2028, significantly mitigates financing risk, a key positive for investors considering a long-term position in a development-stage biotech firm.